



FOR IMMEDIATE RELEASE

C2Sense™ Completes Second Closing of its \$8M Series B Round to Accelerate Halo™, its Digitally Connected Diagnostic Platform

Watertown, Mass., January 4, 2023 – C2Sense, Inc., a technology company developing a suite of diagnostic products for healthcare, wellness and safety, announced today the successful second closing of its \$8M Series B financing round with participation from new and existing investors. The proceeds will be used to fund initial clinical and usability studies in support of their Halo platform.

The Halo platform comprises a high performance, inexpensive diagnostic reader, a user-friendly app (complete with a customizable in-app marketplace for purchasing tests), and a comprehensive cloud-based data backend. Proprietary algorithms enable the Halo diagnostic reader to utilize low cost, off-the-shelf components while maintaining high performance and (as recently published in [Frontiers in Public Health](#)) an extremely low coefficient of variation (CV). These features provide rapid test developers and manufacturers with an inexpensive, customizable pathway to deploy their assays to end-users in point-of-care (POC), point-of-need (PON), and over the counter (OTC)/at-home environments.

“We are committed to creating low-cost, open-sourced, digitally-connected diagnostic solutions so that all people have access to a wide variety of rapid tests and reliable results regardless of income or location,” said Jason Cox, Ph.D., CEO of C2Sense. “Halo is the breakthrough platform that can do that, and we are extremely proud of what we’ve created.”

About Halo

Halo combines proprietary hardware and software designed and developed by C2Sense for use with commercially available colorimetric or fluorescent rapid diagnostic tests in support of healthcare, wellness, and safety. Halo is highly accurate, assay manufacturer agnostic, digitally connected, and easy-to-use. For more information on Halo, visit www.HaloReader.com.

About C2Sense

C2Sense is a technology company with a product portfolio that delivers solutions for rapid diagnostics, authentication, and product viability assurance to reduce loss and harm for all people. As an MIT “Tough Tech” spinout, C2Sense has proven commercial solutions to help with some of the world’s toughest challenges. For more information on C2Sense, visit www.c2sense.com.

Media Inquiries
Contact@c2sense.com